To reduce the development of adverse CVEs among patients with NAFLD and type 2 diabetes, it is also essential to have routine cardiovascular risk assessments and timely implementation of GLP-1RAs and SGLT2 inhibitors. This evidence concerns the gene SLC5A2 and metabolic dysfunction-associated steatotic liver disease.